On 8 June, Anavex Life Sciences Corp - a clinical-stage biopharmaceutical company developing therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) – announced that it has completed enrolment for its ongoing Phase IIb/III study evaluating blarcamesine (formerly known as ANAVEX 2-73) for Alzheimer’s disease (AD). The 48-week Phase 2II/III double-blind, randomised and placebo-controlled is evaluating the safety and efficacy trial of blarcamesine for the treatment of early AD. The recruitment has exceeded the company’s initial target and recruiting 450 participants at 52 sites across US, Europe and Australia. Participants will receive once daily oral doses of either blarcamesine or placebo. Primary and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through ADAS-Cog, ADCS-ADL and CDR-SB. The company expects to announce topline results by mid-2022.
